Press Releases
Search
-
15 Apr 2005
bioMérieux invests in the future of emergency diagnostics
Marcy l’Etoile, France - April 15, 2005. A world leader in the field of in vitro diagnostics, with over 40 years experience in infectious diseases, bioMérieux SA recently confirmed its commitment to t...
-
05 Apr 2005
Affymetrix and bioMérieux Extend Their Agreement on GeneChip® Technology to Breast Cancer Diagnostics
Santa Clara, Calif., US and Marcy l’Etoile, France - April 5, 2005. The agreement includes an option for bioMérieux to use Affymetrix GeneChip® technology in other cancer areas. Affymetrix Inc. (Nasda...
-
25 Mar 2005
NucliSens® miniMAG™, bioMérieux’s next generation nucleic acid extraction platform is now available as CE-IVD approved platform
Marcy l'Etoile, France - March 25, 2005. bioMérieux announces the introduction of the NucliSens miniMAG and NucliSens Magnetic Extraction Reagents as CE-IVD marked products. A major actor in the field...
-
21 Mar 2005
bioMérieux announces its results for 2004
Marcy l'Etoile, France - March 21, 2005. • Operating income up 30% • Net income up 37% • Debt reduced to 28% of shareholders’ equity from 51%...
-
11 Mar 2005
Chinese Academy of Medical Sciences and bioMerieux join resources to fight emerging pathogens
Marcy l'Etoile, France - March 11, 2005. The Chinese Academy of Medical Sciences and bioMérieux announce that they have signed a strategic teaming agreement, aiming at initiating R&D projects in the f...
-
01 Mar 2005
B·R·A·H·M·S AG and bioMérieux SA sign a non-exclusive agreement on the use of Procalcitonin
Marcy l'Etoile, France - March 1st, 2005. B·R·A·H·M·S AG and bioMérieux SA have announced the signature of a non-exclusive agreement on the use of Procalcitonin as a diagnostic marker for severe bacte...
-
10 Feb 2005
bioMérieux launches VITEK® 2 Compact, its new solution for rapid identification of micro-organisms
Marcy l’Etoile, France - February 10, 2005. bioMérieux, a major player in the field of microbiological controls for the pharmaceutical and agri-food industries, introduces VITEK®2 Compact, the newest ...
-
31 Jan 2005
bioMérieux innovates in food quality testing
Marcy l'Etoile, France - January 31, 2005. bioMérieux, world leader in the field of food microbiology controls, extends its product offer dedicated to the food industry with the launch of the TEMPO® s...
-
19 Jan 2005
2004 Sales up 5.2% at Constant Exchange Rates
Marcy l'Etoile, France - January 19, 2005. bioMérieux, a global leader in the field of in vitro diagnostics, today announced its 2004 sales.
-
06 Jan 2005
bioMérieux launches VITEK® 2 Compact to complete its VITEK 2 range
Marcy l’Etoile, France - January 6, 2005. A world leader in the field of in vitro diagnostics, bioMérieux SA (Euronext: FR0010096479 – BIM) completes its VITEK® 2 range of automated microbial identifi...
-
15 Dec 2004
bioMérieux acquires an option to license Applied NeuroSolutions’ Technology to diagnose Alzheimer’s disease
Marcy L’Etoile, France - December 15th, 2004. bioMérieux SA (Euronext: FR0010096479 – BIM) , announces today that it signed a non-exclusive agreement with Applied Neurosolutions granting bioMérieux SA...
-
05 Nov 2004
bioMérieux reveals VIDIA, its new automated immunoanalyser, in Paris at the Journées Internationales de Biologie
Marcy l'Etoile, France - November 5th, 2004. A major player in the in vitro diagnostics marketplace, bioMérieux announces the first official presentation of its new fully automated immunoanalyser, VID...
-
25 Oct 2004
bioMérieux to assess potential of PlasmAcute® Technology for tuberculosis testing
Bergen, Norway - October 25, 2004. Novel Diagnostics ASA and bioMérieux announced today that they have signed an agreement that gives bioMérieux access to patented PlasmAcute® acute phase antibody det...
-
20 Oct 2004
Nine-Month Sales Up 5.6% at Constant Exchange Rates
Marcy l'Etoile, France - October 20th, 2004. bioMérieux, a global leader in the field of in vitro diagnostics, today announced its sales for the first nine months of 2004.
-
07 Oct 2004
bioMérieux signs New Agreements with Gen-Probe
Marcy l'Etoile, France - October 7th, 2004. bioMérieux receives a $ 1 million license fee for access to its markers for blood clotting disorders. bioMérieux to give Gen-Probe an option for the access ...